Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Lymphoma

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 21 articles: HTML format

Single Articles

November 2025
1. BARNA G, Szaloki G, Mark A, Hunyadi A, et al
   CD86, the double agent: Significance of CD86 expression in B-cell malignancies.
   Int J Cancer. 2025;157:1772-1780.
   PubMed     Abstract available
   
   
   October 2025
2. QIU L, Bai S, Cai J, Fang Y, et al
   Antiviral prophylaxis for hepatitis B virus reactivation in T-cell lymphoma patients with resolved hepatitis B virus infection.
   Int J Cancer. 2025 Oct 4. doi: 10.1002/ijc.70186.
   PubMed     Abstract available
   
   
   September 2025
3. RAMASSAMY JL, Tortevoye P, Ntab B, Carles G, et al
   Adult T-cell leukemia/lymphoma in French Guiana (1990-2019): Epidemiology, clinical features, and HTLV-1 genetic diversity in the two main ethnic populations.
   Int J Cancer. 2025 Sep 23. doi: 10.1002/ijc.70164.
   PubMed     Abstract available
   
   
   
4. MOORE A, Kane E, Teras LR, Machiela MJ, et al
   Genetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.
   Int J Cancer. 2025 Sep 5. doi: 10.1002/ijc.70039.
   PubMed     Abstract available
   
   
   August 2025
5. ZHAO J, Zhang Y, Li K, Xu L, et al
   Estimates of global, regional, and national incidence of Hodgkin lymphoma attributable to Human Immunodeficiency virus: A population attributable modeling study.
   Int J Cancer. 2025 Aug 29. doi: 10.1002/ijc.70115.
   PubMed     Abstract available
   
   
   
6. LOPES-ARAUJO HF, Guimaraes RL, Carvalho-Silva WHV
   Correlations between new HIV infections and hospital admissions for non-Hodgkin lymphoma in Brazil.
   Int J Cancer. 2025 Aug 6. doi: 10.1002/ijc.70076.
   PubMed     Abstract available
   
   
   June 2025
7. LIU Y, Lin N, Yi S, Huang H, et al
   Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial.
   Int J Cancer. 2025;156:2158-2168.
   PubMed     Abstract available
   
   
   March 2025
8. DING J, Cheng X, Wang H, Sun Y, et al
   Prognosis prediction in non-Hodgkin lymphoma by assessing lymphoid organs uptake patterns using baseline (18)F-FDG PET/CT.
   Int J Cancer. 2025 Mar 24. doi: 10.1002/ijc.35412.
   PubMed     Abstract available
   
   
   
9. LIANG X, Wu Y, Lu W, Li T, et al
   Latent class analysis-derived classification improves the cancer-specific death stratification of lymphomas: A large retrospective cohort study.
   Int J Cancer. 2025;156:1131-1141.
   PubMed     Abstract available
   
   
   
10. KIM IE JR, Oduor C, Stamp J, Luftig MA, et al
    Incorporation of Epstein-Barr viral variation implicates significance of Latent Membrane Protein 1 in survival prediction and prognostic subgrouping in Burkitt lymphoma.
    Int J Cancer. 2025 Mar 6. doi: 10.1002/ijc.35384.
    PubMed     Abstract available
    
    
    October 2024
11. JAIN R, Huda TI, Paul S, Chobrutskiy A, et al
    Detection of anti-EBV TCR CDR3s associated with better outcomes for EBV-positive, Ugandan cases of Burkitt lymphoma.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35212.
    PubMed     Abstract available
    
    
    September 2024
12. DUELL J, Westin J
    The future of immunotherapy for diffuse large B-cell lymphoma.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35156.
    PubMed     Abstract available
    
    
    
13. BASSIG BA, Shu XO, Friesen MC, Vermeulen R, et al
    Occupational exposure to benzene and risk of non-Hodgkin lymphoma in an extended follow-up of two population-based prospective cohorts of Chinese men and women.
    Int J Cancer. 2024 Sep 2. doi: 10.1002/ijc.35095.
    PubMed     Abstract available
    
    
    August 2024
14. DUSINGIZE JC, Murenzi G, Muhoza B, Businge L, et al
    Cancer risk among people living with Human Immuodeficiency Virus (HIV) in Rwanda from 2007 to 2018.
    Int J Cancer. 2024 Aug 11. doi: 10.1002/ijc.35091.
    PubMed     Abstract available
    
    
    July 2024
15. SARATHKUMARA YD, Xian RR, Liu Z, Yu KJ, et al
    A proteome-wide analysis unveils a core Epstein-Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations.
    Int J Cancer. 2024 Jul 12. doi: 10.1002/ijc.35072.
    PubMed     Abstract available
    
    
    May 2024
16. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
    Changes in mortality associated with different hematologic malignancies during the pandemic in the United States.
    Int J Cancer. 2024;154:1703-1708.
    PubMed     Abstract available
    
    
    March 2024
17. WANG X, Deng L, Ping L, Shi Y, et al
    Germline variants of DNA repair and immune genes in lymphoma from lymphoma-cancer families.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34892.
    PubMed     Abstract available
    
    
    
18. TABORELLI M, Serraino D, Cimaglia C, Furian L, et al
    Cancer mortality after kidney transplantation: A multicenter cohort study in Italy.
    Int J Cancer. 2024;154:842-851.
    PubMed     Abstract available
    
    
    December 2023
19. LUO J, Hendryx M, Rohan TE, Saquib N, et al
    Hysterectomy, oophorectomy and risk of non-Hodgkin's lymphoma.
    Int J Cancer. 2023 Dec 19. doi: 10.1002/ijc.34820.
    PubMed     Abstract available
    
    
    October 2023
20. DU Y, Wang Y, Li Q, Chang X, et al
    Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study.
    Int J Cancer. 2023 Oct 24. doi: 10.1002/ijc.34773.
    PubMed     Abstract available
    
    
    September 2023
21. LINDMARK G, Olsson L, Sitohy B, Israelsson A, et al
    qRT-PCR analysis of CEACAM5, KLK6, SLC35D3, MUC2 and POSTN in colon cancer lymph nodes-An improved method for assessment of tumor stage and prognosis.
    Int J Cancer. 2023 Sep 12. doi: 10.1002/ijc.34718.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.